Latest:
Dr. Brenner on the Role of Trastuzumab Deruxtecan in Gastric Cancer
Warren S. Brenner, MD, discusses the utilization of fam-trastuzumab deruxtecan-nxki (Enhertu) as a HER2-directed therapy in gastric cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Kimberly Perez, MD
Kimberly Perez, MD is the Co-Director, Clinical Research, Division of Gastrointestinal Oncology, and an Assistant Professor of Medicine at Harvard Medical School.
Latest:
Dr Perez on the FDA Approval of Belzutifan for Advanced Pheochromocytoma and Paraganglioma
Kimberly Perez MD, discusses the FDA approval of belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.
Joern-Peter Halle, Global Head of Research at Merck KGaA, Darmstadt, Germany*
Latest:
Discovering New Medicines in Cancer
Our ambition is to outsmart cancer by translating our science into health. The combination of our people and heritage is a particular advantage we have in achieving this goal. Our teams are curious, bold, and driven to deliver potentially transformative medicines to patients with cancer. Our heritage of science-based precision medicine and immuno-oncology means that we can branch into synergies to bridge different aspects of cancer research, in an agile and uncompromising manner. Our research focus is on three key mechanistic pillars: oncogenic pathways; immuno-oncology (IO); and DNA damage response (DDR); and, we are developing new approaches in key tumor types in GI, GU and thoracic cancers, all areas with significant unmet treatment needs. Together, we are transforming cancer care—today and tomorrow.
Catherine C. Coombs, MD
Catherine C. Coombs, MD, is a hematologist-oncologist and associate clinical professor in the Department of Medicine of the Division of Hematology/Oncology at University of California Irvine Health.
Latest:
Emerging Developments for the Treatment of R/R CLL
Panelists discuss how emerging therapies including BTK degraders, bispecific antibodies, and novel BCL-2 inhibitors represent exciting future treatment options for managing CLL patients across different lines of therapy.
Samantha A. Armstrong, MD
Samantha A. Armstrong, MD, is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health
Latest:
Urothelial ESMO 2025 Updates
OncLive partnered with Two Onc Docs to review updates from the 2025 ESMO Congress on bladder cancer management that may change guidelines.
Fay Kastrinos, MD, MPH
Latest:
Understanding Lynch Syndrome and Associated Cancer Risk: Future Preventive Considerations
In this sixth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, shares future considerations for optimizing the identification of Lynch syndrome and other efforts underway to prevent colorectal cancer in those who have this condition.
Meghan K. Berkenstock, MD
Latest:
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Meghan K. Berkenstock, MD, discusses common ocular toxicities associated with the use of novel antibody-drug conjugates, and the subsequent development of mitigation strategies for these treatment-related adverse effects in gynecologic cancers.
Gary Doherty, MRCP, PhD, Cambridge University Hospitals NHS Foundation Trust
Latest:
EGFR+ NSCLC: Advice for Community Oncologists
A panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.